1. Home
  2. KRYS vs SXT Comparison

KRYS vs SXT Comparison

Compare KRYS & SXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KRYS
  • SXT
  • Stock Information
  • Founded
  • KRYS 2015
  • SXT 1882
  • Country
  • KRYS United States
  • SXT United States
  • Employees
  • KRYS N/A
  • SXT N/A
  • Industry
  • KRYS Biotechnology: Biological Products (No Diagnostic Substances)
  • SXT Major Chemicals
  • Sector
  • KRYS Health Care
  • SXT Industrials
  • Exchange
  • KRYS Nasdaq
  • SXT Nasdaq
  • Market Cap
  • KRYS 4.3B
  • SXT 4.6B
  • IPO Year
  • KRYS 2017
  • SXT N/A
  • Fundamental
  • Price
  • KRYS $152.08
  • SXT $111.30
  • Analyst Decision
  • KRYS Strong Buy
  • SXT Buy
  • Analyst Count
  • KRYS 11
  • SXT 2
  • Target Price
  • KRYS $204.27
  • SXT $110.00
  • AVG Volume (30 Days)
  • KRYS 273.6K
  • SXT 480.5K
  • Earning Date
  • KRYS 08-04-2025
  • SXT 07-25-2025
  • Dividend Yield
  • KRYS N/A
  • SXT 1.47%
  • EPS Growth
  • KRYS 109.01
  • SXT 53.07
  • EPS
  • KRYS 4.16
  • SXT 3.17
  • Revenue
  • KRYS $333,448,000.00
  • SXT $1,575,588,000.00
  • Revenue This Year
  • KRYS $40.10
  • SXT $4.93
  • Revenue Next Year
  • KRYS $49.73
  • SXT $5.26
  • P/E Ratio
  • KRYS $36.60
  • SXT $35.17
  • Revenue Growth
  • KRYS 247.53
  • SXT 4.95
  • 52 Week Low
  • KRYS $122.80
  • SXT $66.15
  • 52 Week High
  • KRYS $213.52
  • SXT $114.59
  • Technical
  • Relative Strength Index (RSI)
  • KRYS 58.86
  • SXT 67.95
  • Support Level
  • KRYS $147.35
  • SXT $101.21
  • Resistance Level
  • KRYS $154.99
  • SXT $114.59
  • Average True Range (ATR)
  • KRYS 4.29
  • SXT 2.97
  • MACD
  • KRYS 0.08
  • SXT -0.10
  • Stochastic Oscillator
  • KRYS 66.32
  • SXT 75.41

About KRYS Krystal Biotech Inc.

Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.

About SXT Sensient Technologies Corporation

Sensient Technologies Corp manufactures and markets natural and synthetic colors, flavors, and other specialty ingredients. Sensient's offerings are predominantly applied to consumer-facing products, including food and beverage, cosmetics and pharmaceuticals, nutraceuticals, and personal care industries. Its principal products are flavors, flavor enhancers, ingredients, extracts, and bionutrients, essential oils, dehydrated vegetables and other food ingredients, natural and synthetic food and beverage colors, and others. The company's reportable segments are; Flavors & Extracts, which derive key revenue, Color, Asia Pacific, and Corporate and Other. Geographically, the company generates maximum revenue from North America, followed by Europe, Asia-Pacific, and other regions.

Share on Social Networks: